drugset / Trial / NCT00186498

Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression

NCT00186498

RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to determine whether taking the medication memantine reduces impairment of memory and attention associated with electroconvulsive therapy.

Timeline

Start
2004-02
Primary completion
2006-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown